Brokerages Set Definium Therapeutics, Inc. (NASDAQ:DFTX) Target Price at $63.00

Definium Therapeutics, Inc. (NASDAQ:DFTX) has been given a consensus rating of “Buy” by the twenty research firms that are currently covering the company, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, seventeen have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month price target among brokerages that have updated their coverage on the stock in the last year is $63.00.

Several brokerages have commented on DFTX. Wall Street Zen cut shares of Definium Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, August 8th. Leerink Partners set a $52.00 price target on shares of Definium Therapeutics and gave the company an “outperform” rating in a report on Monday, June 22nd. Stifel Nicolaus upped their price target on shares of Definium Therapeutics from $30.00 to $60.00 and gave the company a “buy” rating in a research report on Wednesday, July 8th. Citigroup restated a “buy” rating on shares of Definium Therapeutics in a research report on Monday, June 22nd. Finally, Needham & Company LLC raised their price objective on shares of Definium Therapeutics from $50.00 to $66.00 and gave the stock a “buy” rating in a research note on Wednesday, August 12th.

Definium Therapeutics Trading Up 0.2%

Shares of NASDAQ DFTX opened at $38.09 on Wednesday. Definium Therapeutics has a 12 month low of $8.77 and a 12 month high of $49.70. The company has a market cap of $5.12 billion, a price-to-earnings ratio of -11.10 and a beta of 2.23. The company has a quick ratio of 6.95, a current ratio of 6.95 and a debt-to-equity ratio of 0.04. The business has a fifty day simple moving average of $43.70 and a 200-day simple moving average of $29.49.

Definium Therapeutics (NASDAQ:DFTX) last released its quarterly earnings results on Thursday, August 6th. The company reported ($1.44) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.89). Sell-side analysts predict that Definium Therapeutics will post -3.02 EPS for the current year.

Insiders Place Their Bets

In related news, CFO Brandi Roberts sold 3,013 shares of the company’s stock in a transaction on Thursday, June 25th. The stock was sold at an average price of $45.03, for a total transaction of $135,675.39. Following the transaction, the chief financial officer directly owned 209,487 shares of the company’s stock, valued at approximately $9,433,199.61. The trade was a 1.42% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, insider Mark Sullivan sold 13,008 shares of the stock in a transaction dated Thursday, June 25th. The stock was sold at an average price of $45.03, for a total value of $585,750.24. Following the completion of the sale, the insider directly owned 320,571 shares of the company’s stock, valued at approximately $14,435,312.13. This represents a 3.90% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last ninety days, insiders sold 67,119 shares of company stock worth $2,887,496. 2.40% of the stock is currently owned by corporate insiders.

Institutional Trading of Definium Therapeutics

A number of hedge funds have recently made changes to their positions in the stock. Russell Investments Group Ltd. boosted its holdings in shares of Definium Therapeutics by 110.4% during the second quarter. Russell Investments Group Ltd. now owns 3,817 shares of the company’s stock worth $25,000 after purchasing an additional 2,003 shares during the period. Nykredit A S acquired a new position in Definium Therapeutics in the 2nd quarter valued at approximately $45,000. BNP Paribas Financial Markets increased its stake in Definium Therapeutics by 56.0% in the 2nd quarter. BNP Paribas Financial Markets now owns 8,417 shares of the company’s stock valued at $55,000 after buying an additional 3,020 shares during the period. Caxton Associates LLP purchased a new stake in Definium Therapeutics in the 3rd quarter worth approximately $126,000. Finally, ExodusPoint Capital Management LP purchased a new stake in Definium Therapeutics in the 4th quarter worth approximately $254,000. 27.91% of the stock is owned by hedge funds and other institutional investors.

Definium Therapeutics Company Profile

Definium Therapeutics, Inc, a clinical stage biopharmaceutical company, develops novel products to treat brain health disorders. The company’s lead product candidates include MM120, which is in phase 3 for the treatment of generalized anxiety disorder and attention deficit hyperactivity disorder; and DT402, a R-enantiomer of 3,4-methylenedioxymethamphetamine, which is in phase 2a clinical trials for the treatment of core symptoms of autism spectrum disorder. The company was formerly known as Mind Medicine (MindMed) Inc and changed its name to Definium Therapeutics, Inc in January 2026.